Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia

Leukemia

Volumn 29, Issue 4, 2015, Pages 981-984

  Huelsemann, M F ^a   Patz, M ^a   Beckmann, L ^a   Brinkmann, K ^a   Otto, T ^b   Fandrey, J ^b   Becker, H J ^a   Theurich, S ^a   Von Bergwelt Baildon, M ^a   Pallasch, C P ^a   Zahedi, R P ^c   Kashkar, H ^a   Reinhardt, H C ^a   Hallek, M ^a   Wendtner, C M ^a,d   Frenzel, L P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^d Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BENDAMUSTINE; BH3 PROTEIN; DORAMAPIMOD; FLUDARABINE; IBRUTINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ABT-737; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; CD40 LIGAND; CHLORMETHINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; NITROPHENOL; OXYGEN; PIPERAZINE DERIVATIVE; PROTEIN BCL X; SULFONAMIDE; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL HYPOXIA; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; LETTER; LEUKEMIA CELL; LYMPHOMA CELL LINE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CELL CULTURE; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BCL-X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CD40 LIGAND; CELL HYPOXIA; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROGEN MUSTARD COMPOUNDS; NITROPHENOLS; OXYGEN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SULFONAMIDES; VIDARABINE;

EID: 84927692085     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.320     Document Type: Letter

References (15)

1. Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365-2372.
2. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
3. Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014; 508: 269-273.
4. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001; 167: 6140-6149.
5. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
6. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118: 3579-3590.
7. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
8. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
9. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-9141.
10. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009; 66: 1326-1336.
11. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 1994; 54: 1425-1430.
12. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 2002; 22: 6401-6407.
13. Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med 2012; 18: 19-28.
14. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005; 25: 4853-4862.
15. Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D. Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells. J Biol Chem 1999; 274: 23570-23576.